The secrecy involved in managing the deal was such that even top-level officials were kept in the dark, company employees said. Every senior officials of the company, whom Business Standard spoke to, admitted that they came to know about the deal through the newspapers. "There will not be any change in the company's functioning until the deal gets closed in March 2009. What we are concerned about is the post-Daiichi takeover situation," an employee said.
Meanwhile, the Federation of Medical Representatives Association of India (FMRAI), the apex body of pharmaceutical sales force has said that it will approach the Ranbaxy management to seek clarification of the post-acquisition prospects of its members (who are employees of Ranbaxy) soon. "We are keenly observing the situation. FMRAI will make its position clear after we meet the Ranbaxy management to discuss several issues, including the current development," D P Dubey, general secretary, FMRAI, said.
It is known that the employees will be keen on settling all labour and trade union-related issues with the company before the acquisition is complete.
Independent pharmaceutical expert and Chryscapital Managing Director Sanjiv Kaul said the chances of a sudden management reshuffle is unlikely.
"Ranbaxy will be the generic arm of Daiichi and both are likely to function independently under different management teams. There should not be any problems," he said.
More From This Section
A Ranbaxy spokesperson informed that Malvinder Mohan Singh, the CEO and managing director of Ranbaxy, had addressed all company employees yesterday itself.
"We have also communicated the development through our internal website. All our employees are working as usual and there is absolutely no problem," he said.